Biological E, Canadian firm to jointly manufacture mRNA vaccines in India

Canadian firm Providence Therapeutics Holdings Inc. and Hyderabad-based Biological E have announced the execution of a term sheet that sets forth the material terms for a definitive licensing and collaboration agreement. It also outlines the terms for sale by Providence of up to 30 million doses of Providence’s proprietary messenger RNA vaccine, PTXCOVID19-B, to Biological E and other End-buyers. This represents the sale of all the remaining 2021 Providence production, plus a portion of the early 2022

Providence production, after accounting for the first sale of Providence vaccines to the Province of Manitoba, Canada. Providence will provide the necessary technology transfer for Biological E to manufacture mRNA vaccines in India, with a minimum production capacity of 600 million doses in 2022 and a target capacity of 1 billion doses. Biological E will be responsible for all clinical development and regulatory activities for the mRNA vaccine in India and other jurisdictions licensed by Biological E.